EP1765403A4 - Combined active and passive targeting of biologically active agents - Google Patents

Combined active and passive targeting of biologically active agents

Info

Publication number
EP1765403A4
EP1765403A4 EP05780057A EP05780057A EP1765403A4 EP 1765403 A4 EP1765403 A4 EP 1765403A4 EP 05780057 A EP05780057 A EP 05780057A EP 05780057 A EP05780057 A EP 05780057A EP 1765403 A4 EP1765403 A4 EP 1765403A4
Authority
EP
European Patent Office
Prior art keywords
passive targeting
combined
biologically active
active
active agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05780057A
Other languages
German (de)
French (fr)
Other versions
EP1765403A2 (en
Inventor
Vaikunth Cuchelkar
Pavla Kopechova
C Matthew Peterson
Jindrich Kopecek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation UURF
Original Assignee
University of Utah Research Foundation UURF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation UURF filed Critical University of Utah Research Foundation UURF
Publication of EP1765403A2 publication Critical patent/EP1765403A2/en
Publication of EP1765403A4 publication Critical patent/EP1765403A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP05780057A 2004-05-10 2005-05-05 Combined active and passive targeting of biologically active agents Withdrawn EP1765403A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56977004P 2004-05-10 2004-05-10
PCT/US2005/015681 WO2005115457A2 (en) 2004-05-10 2005-05-05 Combined active and passive targeting of biologically active agents

Publications (2)

Publication Number Publication Date
EP1765403A2 EP1765403A2 (en) 2007-03-28
EP1765403A4 true EP1765403A4 (en) 2011-03-30

Family

ID=35451414

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05780057A Withdrawn EP1765403A4 (en) 2004-05-10 2005-05-05 Combined active and passive targeting of biologically active agents

Country Status (2)

Country Link
EP (1) EP1765403A4 (en)
WO (1) WO2005115457A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2683393T3 (en) 2011-02-11 2018-07-23 Univ Michigan Regents TRIPEPTIME COMPOSITIONS AND THEIR USE IN TREATING DIABETES
CN111454302B (en) * 2020-04-30 2022-07-05 大连理工大学 Chlorin e6 ferrocene conjugate with light and sound sensitive activity, preparation method and application

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853713A (en) * 1994-02-28 1998-12-29 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
WO1999029303A1 (en) * 1997-12-12 1999-06-17 Samyang Corporation Biodegradable mixed polymeric micelles for gene delivery
WO2001091798A2 (en) * 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
US20020099041A1 (en) * 2000-10-06 2002-07-25 Gallop Mark A. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
WO2003046185A1 (en) * 2001-11-28 2003-06-05 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
WO2003070982A1 (en) * 2002-02-22 2003-08-28 Avaris Ab Complex comprising at least two biospecific elements separated by a nucleic acid linker e.g. for identification of drug delivery candidates. combinatorial library of such complexes
WO2004009136A2 (en) * 2002-07-22 2004-01-29 Psimei Pharmaceuticals Plc Conjugates of n-hydroxypropymethacrylamide-methacrylate copolymer with nuclide activation agent and/or anti-cancer compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853713A (en) * 1994-02-28 1998-12-29 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
WO1999029303A1 (en) * 1997-12-12 1999-06-17 Samyang Corporation Biodegradable mixed polymeric micelles for gene delivery
WO2001091798A2 (en) * 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
US20020099041A1 (en) * 2000-10-06 2002-07-25 Gallop Mark A. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
WO2003046185A1 (en) * 2001-11-28 2003-06-05 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
WO2003070982A1 (en) * 2002-02-22 2003-08-28 Avaris Ab Complex comprising at least two biospecific elements separated by a nucleic acid linker e.g. for identification of drug delivery candidates. combinatorial library of such complexes
WO2004009136A2 (en) * 2002-07-22 2004-01-29 Psimei Pharmaceuticals Plc Conjugates of n-hydroxypropymethacrylamide-methacrylate copolymer with nuclide activation agent and/or anti-cancer compounds

Also Published As

Publication number Publication date
WO2005115457A2 (en) 2005-12-08
EP1765403A2 (en) 2007-03-28
WO2005115457A3 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
EP1635876A4 (en) Improved intra-dermal delivery of biologically active agents
IL183252A0 (en) Solid formulations of liquid biologically active agents
EP1740197A4 (en) Therapeutic enzyme formulations and uses thereof
IL178595A0 (en) 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
PL2213168T3 (en) Pesticidal combination of active agents
IL177098A0 (en) Controlled and sustained delivery of nucleic acid based therapeutic agents
GB0522503D0 (en) Integration of micro-electro mechanical systems and active circuitry
IL170454A (en) Transdermal or transmucosal formulations of active agents and uses thereof
IL172841A0 (en) Active agents combination exhibiting insecticidal and acaricide properties
IL180887A0 (en) Quinoline derivatives and insecticide comprising thereof as active ingredient
IL181801A0 (en) Transdermal delivery of hydrophobic bioactive agents
PL1715743T3 (en) Combinations of insecticide active agents based on thiacloprid and pyrethroids
GB0410725D0 (en) Pyrrolobenzodiazepine therapeutic agents
DE602005021918D1 (en) FINAL BODY AND TREADMILL
GB0524958D0 (en) Transdermal administration of active agents
EP2099441A4 (en) Metal delivery agents and therapeutic uses of the same
EP1758605A4 (en) Prouroguanylin as therapeutic and diagnostic agents
EP1781685A4 (en) Therapeutic and diagnostic agents
GB0509749D0 (en) A method of delivering a biologically active agent
ZA200600098B (en) Active agents combination exhibiting insecticidal and acaricide properties
HK1109581A1 (en) Pharmaceutical use of graptopetalum and related plants
IL181300A0 (en) Photosensitizer formulations and uses thereof
EP1667656A4 (en) Compositions and methods for delivery of biologically active agents
EP1765403A4 (en) Combined active and passive targeting of biologically active agents
EP1701736A4 (en) Therapeutic agents and uses therefor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061204

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

DAX Request for extension of the european patent (deleted)
PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/00 20060101ALI20090709BHEP

Ipc: C07K 14/00 20060101AFI20090709BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20110228

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/48 20060101ALI20110222BHEP

Ipc: C07K 16/00 20060101ALI20110222BHEP

Ipc: C07K 14/00 20060101AFI20090709BHEP

17Q First examination report despatched

Effective date: 20110620

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150204